Novavax to make COVID-19 vaccine shots in Canada

  • In US
  • 2022-12-07 15:44:33Z
  • By Reuters

(Reuters) - Novavax Inc said on Wednesday it will manufacture its COVID-19 vaccine in Canada after the country's health regulator allowed its use in children aged between 12 and 17 years as a primary series of shots.

Production of test batches of the protein-based vaccine, Nuvaxovid, will begin at the Montreal manufacturing center by early 2023, the company said.

The agency's approval was based on a late-stage study which showed the vaccine was effective against COVID-19 in children aged between 12 and 17 years.

Earlier this year, the Canadian health regulator had allowed the use of Novavax's vaccine for primary series and as a booster in adults above 18 years of age.

Hurt by a global supply glut in COVID-19 vaccine and waning demand, Novavax cut its full-year revenue forecast last month to a range of $2 billion and $2.3 billion. Shots from rivals Pfizer/BioNtech and Moderna were approved last year for initial vaccination of adolescents in Canada, hurting the vaccine maker further.

Shares of the Maryland-based company rose 5% to $17.64 in early trade.

(Reporting by Khushi Mandowara; Editing by Krishna Chandra Eluri)


More Related News

Canada province experiments with decriminalising hard drugs
Canada province experiments with decriminalising hard drugs

Cocaine, heroin and fentanyl will be allowed in small quantities in Vancouver and its surrounding province.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: US